长春瑞滨联合顺铂治疗晚期非小细胞肺癌疗效观察

目的观察国产长春瑞滨（NVB）联合顺铂（DDP）治疗晚期非小细胞肺癌的疗效及毒副反应。方法52例晚期NSCLC中男37例，女15例；鳞癌35例，腺癌17例；ⅢA期9例，ⅢB期15例，Ⅳ期28例；初治42例，复治10例；采用长春瑞滨（NVB）25mg／m。第1，8天静滴；顺铂（DDP）25mg／m^2，第1～3天静滴，21d为一周期。结果完全缓解（CR）1例，部分缓解（PR）20例，稳定（SD）27例，进展（PD）4例，总有效率为40．4％。中位疾病进展时间5．6个月，中位生存期11个月，一年生存率46．2％。主要毒副反应为Ⅰ、Ⅱ度骨髓抑制53．8％（28／52），恶心、呕吐发生率为30．8％，其次为静脉炎，发生率11．5％。结论NP方案治疗晚期NSCLC疗效确切，毒副反应可耐受，价格相对便宜，为符合我国国情的治疗晚期非小细胞肺癌的方案。

Clinical Effect Vinorebine and Cisplatin in Advanced Non-Small Cell Lung Cancer

Objective To evaluate the efficacy and toxicity of Vinorelbine combined with Cisplatin（NP regimen） in the treatment of advanced non-small cell lung cancer （NSCLC）. Methods In 52 patients with advanced NSCLC, there were 35 with squamous carcinoma, 17 with lung adenocarcinoma,37 males and 15 females,9 patients with stage ⅢA disease, 15 patients with stage Ⅲ B disease and 28 patients with stage Ⅳ. 42 patients had no prior chemotherapy and 10 patients received previous chemotherapy. NVB 25 mg/m^2, d1, d8;cisplatin 25 mg/m^2, d 1-3 ;21 days was a cycle. Results Partial response was observed in 20 cases, noresponse in 27 cases and progression in 4 cases. The overall response rate was 40.4%. Median time to progression（TTP） was 5.6 months. Median survival duration was 11 months, one year survival rate was 46.2%. The main toxicities were grade Ⅰ - Ⅱ myelosuppression 53.8% ,nausea and vomiting were observed in 30.8% ,phlebitis,in 11.5%. Conclusion The results indicate NP regimen for advanced NSCLC is promise, the toxicities was mild and tolerable.